Inoherb (相宜本草) has once again failed in its attempt to go public, as it has ended its IPO guidance collaboration with China International Capital Corporation (CICC). This marks the second attempt by the Chinese skincare brand to enter the capital market, following its failure in 2014 due to internal disputes. Despite a strong sales peak in 2013, the brand has faced significant challenges in recent years, including a drop in market share and unsuccessful shifts in business strategy. While Inoherb had hoped to capitalize on the growing online market, it has struggled to create standout products that resonate with consumers, especially in the competitive and fast-evolving skincare sector.